| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.
|
Lancet
|
2012
|
2.43
|
|
2
|
Structural and kinetic basis for heightened immunogenicity of T cell vaccines.
|
J Exp Med
|
2005
|
2.22
|
|
3
|
The arthritis-associated HLA-B*27:05 allele forms more cell surface B27 dimer and free heavy chain ligands for KIR3DL2 than HLA-B*27:09.
|
Rheumatology (Oxford)
|
2013
|
2.14
|
|
4
|
Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins.
|
Blood
|
2009
|
1.68
|
|
5
|
Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts.
|
Arthritis Rheum
|
2010
|
1.52
|
|
6
|
microRNA profiling in Epstein-Barr virus-associated B-cell lymphoma.
|
Nucleic Acids Res
|
2010
|
1.32
|
|
7
|
Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1.
|
Blood
|
2011
|
1.32
|
|
8
|
Rational development of high-affinity T-cell receptor-like antibodies.
|
Proc Natl Acad Sci U S A
|
2009
|
1.23
|
|
9
|
Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes.
|
Arthritis Res Ther
|
2006
|
1.17
|
|
10
|
Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer.
|
Int J Cancer
|
2006
|
1.14
|
|
11
|
Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity.
|
Cancer Immunol Immunother
|
2002
|
1.08
|
|
12
|
Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.
|
Eur J Immunol
|
2004
|
1.04
|
|
13
|
Serological identification of breast cancer-related antigens from a Saccharomyces cerevisiae surface display library.
|
Int J Cancer
|
2005
|
1.03
|
|
14
|
Inhibiting HLA-B27 homodimer-driven immune cell inflammation in spondylarthritis.
|
Arthritis Rheum
|
2012
|
1.01
|
|
15
|
MicroRNA-142 is mutated in about 20% of diffuse large B-cell lymphoma.
|
Cancer Med
|
2012
|
1.01
|
|
16
|
Quantitative analysis of scanning tunneling microscopy images of mixed-ligand-functionalized nanoparticles.
|
Langmuir
|
2013
|
1.01
|
|
17
|
Infectious port complications are more frequent in younger patients with hematologic malignancies than in solid tumor patients.
|
Oncology
|
2008
|
0.99
|
|
18
|
A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma.
|
Oncology
|
2012
|
0.98
|
|
19
|
Directed evolution for improved secretion of cancer-testis antigen NY-ESO-1 from yeast.
|
Protein Expr Purif
|
2006
|
0.98
|
|
20
|
Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata.
|
Eur Heart J
|
2011
|
0.97
|
|
21
|
Expression of aberrant HLA-B27 molecules is dependent on B27 dosage and peptide supply.
|
Ann Rheum Dis
|
2013
|
0.96
|
|
22
|
MicroRNA profiling of Epstein-Barr virus-associated NK/T-cell lymphomas by deep sequencing.
|
PLoS One
|
2012
|
0.95
|
|
23
|
Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg.
|
Int J Cancer
|
2009
|
0.92
|
|
24
|
Serological immune response to cancer testis antigens in patients with pancreatic cancer.
|
Int J Cancer
|
2006
|
0.92
|
|
25
|
Treatment of POEMS syndrome with bevacizumab.
|
Haematologica
|
2007
|
0.92
|
|
26
|
Antibody inhibiting enzymatic activity of tumour-associated carbonic anhydrase isoform IX.
|
Eur J Pharmacol
|
2011
|
0.91
|
|
27
|
Simultaneous integrated boost intensity-modulated radiotherapy (SIB‑IMRT) in nasopharyngeal cancer.
|
Strahlenther Onkol
|
2010
|
0.89
|
|
28
|
Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
|
J Transl Med
|
2013
|
0.89
|
|
29
|
Temsirolimus is highly effective as third-line treatment in chromophobe renal cell cancer.
|
Case Rep Oncol
|
2011
|
0.88
|
|
30
|
High-resolution scanning tunneling microscopy characterization of mixed monolayer protected gold nanoparticles.
|
ACS Nano
|
2013
|
0.87
|
|
31
|
Cross-presentation of HLA class I epitopes from influenza matrix protein produced in Saccharomyces cerevisiae.
|
Vaccine
|
2006
|
0.86
|
|
32
|
Functional humanization of an anti-CD30 Fab fragment for the immunotherapy of Hodgkin's lymphoma using an in vitro evolution approach.
|
Protein Eng Des Sel
|
2005
|
0.86
|
|
33
|
Targeted bioactivity of membrane-anchored TNF by an antibody-derived TNF fusion protein.
|
J Immunol
|
2004
|
0.85
|
|
34
|
Diagnosis and treatment of mantle cell lymphoma.
|
Swiss Med Wkly
|
2013
|
0.84
|
|
35
|
Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).
|
BMC Cancer
|
2012
|
0.84
|
|
36
|
Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies.
|
Clin Cancer Res
|
2012
|
0.82
|
|
37
|
Recombinant antigen expression on yeast surface (RAYS) for the detection of serological immune responses in cancer patients.
|
Cancer Immun
|
2003
|
0.82
|
|
38
|
Diagnosis and treatment of diffuse large B-cell lymphoma.
|
Swiss Med Wkly
|
2012
|
0.82
|
|
39
|
Use of spontaneous Epstein-Barr virus-lymphoblastoid cell lines genetically modified to express tumor antigen as cancer vaccines: mutated p21 ras oncogene in pancreatic carcinoma as a model.
|
Hum Gene Ther
|
2002
|
0.82
|
|
40
|
Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells.
|
Clin Cancer Res
|
2006
|
0.82
|
|
41
|
Successful Salvage Chemotherapy with FOLFIRINOX for Recurrent Mixed Acinar Cell Carcinoma and Ductal Adenocarcinoma of the Pancreas in an Adolescent Patient.
|
Case Rep Oncol
|
2013
|
0.81
|
|
42
|
Daily Pomegranate Intake Has No Impact on PSA Levels in Patients with Advanced Prostate Cancer - Results of a Phase IIb Randomized Controlled Trial.
|
J Cancer
|
2013
|
0.81
|
|
43
|
Efficiency of T-cell costimulation by CD80 and CD86 cross-linking correlates with calcium entry.
|
Immunology
|
2009
|
0.81
|
|
44
|
Differential presentation of tumor antigen-derived epitopes by MHC-class I and antigen-positive tumor cells.
|
Int J Cancer
|
2008
|
0.80
|
|
45
|
Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim.
|
Ann Hematol
|
2010
|
0.80
|
|
46
|
Potential use of humanized antibodies in the treatment of breast cancer.
|
Expert Rev Anticancer Ther
|
2006
|
0.79
|
|
47
|
Diagnosis and treatment of follicular lymphoma.
|
Swiss Med Wkly
|
2011
|
0.79
|
|
48
|
Structure-activity profiles of Ab-derived TNF fusion proteins.
|
J Immunol
|
2006
|
0.79
|
|
49
|
MHC-peptide-specific antibodies reveal inefficient presentation of an HLA-A*0201-restricted, Melan-A-derived peptide after active intracellular processing.
|
Eur J Immunol
|
2007
|
0.79
|
|
50
|
Images in cardiovascular medicine. Infarction-like electrocardiographic changes due to a myocardial metastasis from a primary lung cancer.
|
Circulation
|
2007
|
0.78
|
|
51
|
Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T-cells in a cell-free system.
|
Anticancer Res
|
2013
|
0.78
|
|
52
|
Haematopoietic stem cell transplantation: activity in Switzerland compared with surrounding European countries.
|
Swiss Med Wkly
|
2013
|
0.78
|
|
53
|
Tumor-specific crosslinking of GITR as costimulation for immunotherapy.
|
J Immunother
|
2010
|
0.78
|
|
54
|
Cryptic epitopes induce high-titer humoral immune response in patients with cancer.
|
J Immunol
|
2010
|
0.78
|
|
55
|
Abdominal pain in a patient with acute lymphoblastic leukaemia.
|
Ann Hematol
|
2009
|
0.78
|
|
56
|
Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation.
|
Oncology
|
2010
|
0.77
|
|
57
|
Characterization of Hap/BAG-1 variants as RP1 binding proteins with antiapoptotic activity.
|
Int J Cancer
|
2005
|
0.77
|
|
58
|
Sequential cancer immunotherapy: targeted activity of dimeric TNF and IL-8.
|
Cancer Immun
|
2009
|
0.77
|
|
59
|
Autologous stem cell transplantation: leukapheresis product has anti-angiogenic effects in vivo correlating with neutrophil-derived VEGFR1.
|
Anticancer Res
|
2011
|
0.77
|
|
60
|
Fibroblast activation protein increases metastatic potential of fibrosarcoma line HT1080 through upregulation of integrin-mediated signaling pathways.
|
Clin Exp Metastasis
|
2015
|
0.77
|
|
61
|
NY-ESO-1 protein glycosylated by yeast induces enhanced immune responses.
|
Yeast
|
2010
|
0.76
|
|
62
|
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad antibody responses in humans, a RAYS-based analysis.
|
Int J Oncol
|
2011
|
0.76
|
|
63
|
Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo.
|
Cancer Sci
|
2008
|
0.75
|
|
64
|
RP1 is a phosphorylation target of CK2 and is involved in cell adhesion.
|
PLoS One
|
2013
|
0.75
|
|
65
|
Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone).
|
Leuk Lymphoma
|
2012
|
0.75
|
|
66
|
Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas.
|
Virchows Arch
|
2013
|
0.75
|
|
67
|
Scalable patterning of one-dimensional dangling bond rows on hydrogenated Si(001).
|
ACS Nano
|
2013
|
0.75
|
|
68
|
Prognostic factors for survival in lymphoma patients after autologous stem cell transplantation.
|
Swiss Med Wkly
|
2013
|
0.75
|
|
69
|
Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience.
|
Swiss Med Wkly
|
2011
|
0.75
|
|
70
|
Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP.
|
Ann Hematol
|
2010
|
0.75
|
|
71
|
Yeast-based identification of prostate tumor antigens provides an effective vaccine platform.
|
Anticancer Res
|
2010
|
0.75
|